UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 12

of 'Cancer pain management: General principles and risk management for patients receiving opioids'

12
TI
Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group.
AU
Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT, Cancer Pain Outcome Research Study Group (CPOR SG) Investigators
SO
Br J Cancer. 2009;100(10):1566. Epub 2009 Apr 28.
 
Most patients with advanced or metastatic cancer experience pain and despite several guidelines, undertreatment is well documented. A multicenter, open-label, prospective, non-randomised study was launched in Italy in 2006 to evaluate the epidemiology, patterns and quality of pain care of cancer patients. To assess the adequacy of analgesic care, we used a standardised measure, the pain management index (PMI), that compares the most potent analgesic prescribed for a patient with the reported level of the worst pain of that patient together with a selected list of clinical indicators. A total of 110 centres recruited 1801 valid cases. 61% of cases were received a WHO-level III opioid; 25.3% were classified as potentially undertreated, with wide variation (9.8-55.3%) according to the variables describing patients, centres and pattern of care. After adjustment with a multivariable logistic regression model, type of recruiting centre, receiving adjuvant therapy or not and type of patient recruited (new or already on follow-up) had a significant association with undertreatment. Non-compliance with the predefined set of clinical indicators was generally high, ranging from 41 to 76%. Despite intrinsic limitationsof the PMI that may be considered as an indicator of the poor quality of cancer pain care, results suggest that the recourse to WHO third-level drugs still seems delayed in a substantial percentage of patients. This delay is probably related to several factors affecting practice in participating centres and suggests that the quality of cancer pain management in Italy deserves specific attention and interventions aimed at improving patients' outcomes.
AD
Center for the Evaluation and Research on Pain (CERP) Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. apolone@marionegri.it
PMID